Vitality Watch

Dossier pubmed review 11-aug-2026
Narrative review or expert overview without new data

Beyond senescence entry: Individual-cell fates, population outcomes and therapeutic implications in ageing and disease.

Key claim: Senescence entry does not fix a single outcome: individual cells may stay arrested, die, shed, or rarely escape, while harmful persistence often reflects failed population resolution, so therapies must preserve beneficial senescence, clear or modulate persistent populations, or block tumour-cell recovery.

Abstract

Cellular senescence is a stress-response program characterized by durable proliferative arrest, but senescence entry does not determine a single biological outcome. Confusion between the fate of an individual cell and the behavior of a senescent-cell population has obscured interpretation across development, ageing and disease. This Review develops a fate-resolved framework that distinguishes continued arrest, cell death, physical shedding and, under restricted conditions, sustained proliferative recovery from population-level resolution or persistence. We reserve senescence escape for sustained proliferation by the same cell or lineage after validated senescence entry; failed resolution is instead one process that can produce persistence. We examine how checkpoint integrity, chromatin organization, metabolism, secretory signaling and immune surveillance shape these outcomes in development, tissue repair, ageing-associated disorders and cancer. The strength of evidence differs sharply by context. Longitudinal cancer models provide the clearest support for strict escape, alongside a restricted developmental lineage-tracing example, whereas fibrosis, neurodegeneration and metabolic or vascular disease more often support population persistence or impaired resolution without demonstrated cell-cycle re-entry. Accordingly, static markers, single-cell and spatial profiles, and computational trajectories can identify senescence-associated states but cannot establish subsequent fate without lineage tracing, live imaging or equivalent temporal evidence. Therapeutic strategies should therefore be matched to the dominant biological problem: preserving beneficial physiological senescence, resolving or modulating harmful persistent populations, or preventing recovery of residual senescent tumour cells. Because most approaches remain preclinical or early-stage, translation will require appropriate timing, cell-type specificity and protection of beneficial senescent populations.

Why this matters

Most senolytic and senomorphic development treats ‘senescent cell’ as a uniform target, but this review argues entry into senescence is a branch point rather than an endpoint — cells can resolve, die, be cleared, or escape back to proliferation, and pathology tracks population-level failure to resolve. That reframing separates the therapeutic logic for beneficial (wound, tumor-suppressive) senescence, persistent inflammaging pools, and tumor-cell reawakening, and sharpens what a senotherapeutic actually needs to do in a given tissue context.

Source

Link

Briefing card

Beyond senescence entry: Individual-cell fates, population outcomes and therapeutic implications in ageing and disease.
Stage: review · pubmed · 11-aug-2026

Senescence entry does not fix a single outcome: individual cells may stay arrested, die, shed, or rarely escape, while harmful persistence often reflects failed population resolution, so therapies must preserve beneficial senescence, clear or modulate persistent populations, or block tumour-cell recovery.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.arr.2026.103293

build build 880 · 2bcef25 · 2026-11-18